Cellectis SA
PAR:ALCLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cellectis SA
Net Issuance of Debt
Cellectis SA
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cellectis SA
PAR:ALCLS
|
Net Issuance of Debt
-$16.2m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-38%
|
|
|
Valneva SE
PAR:VLA
|
Net Issuance of Debt
€61k
|
CAGR 3-Years
-88%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
-45%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Net Issuance of Debt
€65.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Net Issuance of Debt
-€6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Net Issuance of Debt
-$367k
|
CAGR 3-Years
55%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Net Issuance of Debt
€16.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Cellectis SA
Glance View
Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. The company is headquartered in Paris, Ile-De-France and currently employs 345 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
See Also
What is Cellectis SA's Net Issuance of Debt?
Net Issuance of Debt
-16.2m
USD
Based on the financial report for Dec 31, 2025, Cellectis SA's Net Issuance of Debt amounts to -16.2m USD.
What is Cellectis SA's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 10Y
-38%
The average annual Net Issuance of Debt growth rates for Cellectis SA have been -35% over the past three years , and -38% over the past ten years .
